Log in

Recce Pharmaceuticals Stock Price, News & Analysis (ASX:RCE)

-0.01 (-3.70 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
Now: A$0.26
50-Day Range
MA: A$0.26
52-Week Range
Now: A$0.26
Volume142,188 shs
Average VolumeN/A
Market Capitalization$27.85 million
P/E RatioN/A
Dividend YieldN/A
Recce Pharmaceuticals Ltd, a biotechnology company, researches and develops antibiotic drugs in Australia. The company focuses on the development of RECCE 327 that helps to address the problem of antibiotic resistant superbugs. It also develops drugs for the treatment of stomach ulcers and diarrhea. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Phone61 2 8075 4585



Sales & Book Value

Annual Sales$679,624.00
Cash FlowA$0.00 per share
Book ValueA$0.00 per share



Market Cap$27.85 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RCE News and Ratings via Email

Sign-up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter.

Recce Pharmaceuticals (ASX:RCE) Frequently Asked Questions

What is Recce Pharmaceuticals' stock symbol?

Recce Pharmaceuticals trades on the ASX under the ticker symbol "RCE."

Has Recce Pharmaceuticals been receiving favorable news coverage?

News headlines about RCE stock have been trending somewhat negative this week, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Recce Pharmaceuticals earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Recce Pharmaceuticals.

Who are some of Recce Pharmaceuticals' key competitors?

What other stocks do shareholders of Recce Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Recce Pharmaceuticals investors own include FlexiGroup (FXL), ASE Technology (ASX), IMMUTEP LTD/S (IMMP), Mavenir Systems (MVNR), Organovo (ONVO), Micron Technology (MU), Seres Therapeutics (MCRB), First Graphene (FGR), Turtle Beach (HEAR) and Cree (CREE).

Who are Recce Pharmaceuticals' key executives?

Recce Pharmaceuticals' management team includes the folowing people:
  • Dr. Graham John Hamilton Melrose BSc(Hons), Ph.D., MBA, FRACI, CChem, FAICD, Exec. Chairman & Chief Research Officer (Age 85)
  • Mr. James Hamilton-Bray Graham, Exec. Director and Exec. Director of Marketing & Bus. Devel.
  • Ms. Michele Dilizia, Exec. Director and Exec. Director of Regulatory Affairs & Microbiology
  • Dr. Justin Ward, Principal Quality Chemist
  • Mr. Justin Reynolds, Chief Financial Officer

What is Recce Pharmaceuticals' stock price today?

One share of RCE stock can currently be purchased for approximately A$0.26.

How big of a company is Recce Pharmaceuticals?

Recce Pharmaceuticals has a market capitalization of $27.85 million and generates $679,624.00 in revenue each year. View Additional Information About Recce Pharmaceuticals.

What is Recce Pharmaceuticals' official website?

The official website for Recce Pharmaceuticals is http://www.recce.com.au/.

How can I contact Recce Pharmaceuticals?

The company can be reached via phone at 61 2 8075 4585.

MarketBeat Community Rating for Recce Pharmaceuticals (ASX RCE)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  7 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  14
MarketBeat's community ratings are surveys of what our community members think about Recce Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel